Soon-Shiong’s ‘moonshot’ may not have left the atmosphere
Four years ago, Dr. Patrick Soon-Shiong promised to “develop an effective vaccine-based immunotherapy to combat cancer by 2020.” Cut to the present and the billionaire’s initiative has been largely silent, with all signs pointing to marginal progress at best.
As STAT’s Rebecca Robbins reports, Soon-Shiong had promised to enroll 20,000 cancer patients in trials testing novel approaches to the disease. According to public records, his initiative has recruited about a quarter of that at most. And the resulting data come from small, uncontrolled trials, leaving outside experts dubious of the effort.
In the meantime, Soon-Shiong’s major bets in biotech have languished. NantHealth, which sells software and diagnostic tests, and NantKwest, an immunotherapy company, have each lost more than 90% of their market value since going public.
Read more.
As STAT’s Rebecca Robbins reports, Soon-Shiong had promised to enroll 20,000 cancer patients in trials testing novel approaches to the disease. According to public records, his initiative has recruited about a quarter of that at most. And the resulting data come from small, uncontrolled trials, leaving outside experts dubious of the effort.
In the meantime, Soon-Shiong’s major bets in biotech have languished. NantHealth, which sells software and diagnostic tests, and NantKwest, an immunotherapy company, have each lost more than 90% of their market value since going public.
Read more.
.png)
No hay comentarios:
Publicar un comentario